Floatz logo

MANNITOL

GBM

Northwell HealthSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the GBM cohort.

Asset / SponsorPhaseRating
Lapatinib
National Cancer Institute (NCI)
Phase 2BB
LENVATINIB
Tel Aviv Medical Center
Phase 2BB
CHLOROTOXIN
TransMolecular
Phase 2BB
FET
Thomas Hope
Phase 2B
Silevertinib
Black Diamond Therapeutics, Inc.
Phase 2B

View all 18 →

Same molecule, other indications

MANNITOL is also rated in:

cystic fibrosisDormant
BB
Indicative ·
69 / 100
View asset →
Intracranial HypertensionDormant
BB
Indicative ·
67 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →